SC
SCLX.US Scilex Holding Company
- Market cap
- USD 4.52M
- P/E
- -
- P/B
- 28.85x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is SCLX.US undervalued?
Graham numberThe Graham number of Scilex Holding Company cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Scilex Holding Company fundamental analysis
No fundamental analysis for Scilex Holding Company yet.
Scilex Holding Company stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Scilex Holding Company
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine …
Full company profileScilex Holding Company financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Scilex Holding Company annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 21.0M | 23.6M | 31.3M | 38.0M | 46.7M | 56.6M | 30.3M | 32.5M |
| Gross Profit | 15.2M | 21.4M | 27.7M | 27.2M | 31.1M | 39.9M | 15.0M | 10.6M |
| Operating Income | -139M | -35.3M | -35.8M | -50.6M | -105M | -83.4M | -272M | -123M |
| EBITDA | -158M | -31.5M | -72.9M | -9.80M | -109M | -66.8M | -358M | -131M |
| Net Income | -179M | -47.5M | -88.4M | -23.4M | -114M | -72.8M | -359M | -314M |
| EPS | -44 | -12 | -23 | -6.09 | -31 | -10 | -33 | -45 |
| Balance Sheet | ||||||||
| Total Assets | - | 81.5M | 77.9M | 86.5M | 101M | 93.0M | 365M | 254M |
| Total Liabilities | - | 223M | 302M | 50.3M | 274M | 286M | 577M | 564M |
| Shareholders' Equity | - | -142M | -224M | 36.2M | -173M | -193M | -208M | -308M |
| Cash & Short-term Investments | - | 4.84M | 4.34M | 2.18M | 3.92M | 3.27M | 11.0M | 581K |
| Total Debt | - | 139M | 155M | 1.41M | 128M | 38.0M | 133M | 95.6M |
| Cash Flow | ||||||||
| Operating Cash Flow | -60.4M | -31.5M | -28.7M | -21.3M | -20.7M | 19.3M | 3.82M | -15.7M |
| Capital Expenditure | 584K | 25.0K | 7.00K | 2.07M | 330K | 600K | 133K | 11.0M |
| Free Cash Flow | -61.0M | -31.5M | -28.7M | -23.3M | -21.0M | 18.7M | 3.68M | -26.7M |
| Ratios | ||||||||
| ROE | - | - | - | -64.5% | - | - | - | - |
| ROA | - | -58.3% | -113.5% | -27.0% | -112.9% | -78.3% | -98.3% | -123.7% |
| Net Profit Margin | -849.1% | -201.7% | -282.4% | -61.4% | -244.6% | -128.7% | -1,185.8% | -964.4% |
| Debt to Equity | - | - | - | 0.04x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Scilex Holding Company dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 10.0M | 2.69 | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1606:1000 on Jun 16, 2026.
Who owns Scilex Holding Company
- Insiders 11.67%
- Institutions 9.45%
- Public & others 78.89%
- Shares outstanding 7.03M
- Free float 5.69M
Top funds holding SCLX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 218K | 3.09% | 0.00% | Sep 2026 |
| iShares Micro-Cap ETF | 23.9K | 0.34% | 0.00% | Oct 2026 |
| T. Rowe Price Extended Equity Market Idx | 6.90K | 0.10% | 0.00% | Sep 2026 |
| Vanguard MStar Inst Ttl StkMktIdxInstlPl | 3.81K | 0.05% | 0.00% | Sep 2026 |
| Vanguard Balanced Index Inv | 3.75K | 0.05% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 2.94K | 0.04% | 0.00% | Sep 2026 |
| SWC (CH) IPF I IEF SmCp Wld ex CH NT CHF | 1.69K | 0.02% | 0.00% | Sep 2026 |
| 1290 VT Micro Cap K | 1.68K | 0.02% | 0.00% | Sep 2026 |
| Xtrackers Russell 2000 ETF 1C | 800.00 | 0.01% | 0.00% | Sep 2026 |
| KLP AksjeGlobal Small Cap Indeks S | 290.00 | 0.00% | 0.00% | Sep 2026 |
| Belfund SICAV Belinvest Equity A USD Acc | 221.00 | 0.00% | 0.00% | Sep 2026 |
| State Street Balanced Index K | 120.00 | 0.00% | 0.00% | Sep 2026 |
| Avantis Total Equity Markets ETF | 80.00 | 0.00% | 0.00% | Oct 2026 |
| CIBC US Broad Market Index | 53.00 | 0.00% | 0.00% | Aug 2026 |
| LVIP Dimensional US Core Equity 2 Std | 39.00 | 0.00% | 0.00% | Sep 2026 |
Top institutions holding SCLX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Capital Management, LLC | 301K | 4.28% | +14.10% | Jun 2026 |
| BlackRock Inc | 109K | 1.56% | +6.44% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 45.8K | 0.65% | +15.54% | Jun 2026 |
| Jacobs Levy Equity Management, Inc. | 41.2K | 0.59% | 0.00% | Jun 2026 |
| State Street Corp | 35.4K | 0.50% | 0.00% | Jun 2026 |
| UBS Group AG | 33.4K | 0.47% | +416.02% | Jun 2026 |
| Renaissance Technologies Corp | 31.4K | 0.45% | -5.14% | Sep 2026 |
| Citadel Advisors Llc | 27.5K | 0.39% | 0.00% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 20.9K | 0.30% | 0.00% | Jun 2026 |
| Northern Trust Corp | 15.0K | 0.21% | +0.09% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 4.03K | 0.06% | -66.32% | Jun 2026 |
| Vanguard Global Advisers, LLC | 2.94K | 0.04% | 0.00% | Jun 2026 |
| Advisor Group Holdings, Inc. | 2.34K | 0.03% | +2,286.73% | Jun 2026 |
| Creative Financial Designs Inc | 1.85K | 0.03% | 0.00% | Jun 2026 |
| JONES FINANCIAL COMPANIES LLLP | 1.76K | 0.02% | +133.38% | Jun 2026 |
| Royal Bank of Canada | 1.75K | 0.02% | +9.34% | Jun 2026 |
| Larson Financial Group, LLC | 1.42K | 0.02% | +3,278.57% | Jun 2026 |
| MetLife Investment Management, LLC | 1.09K | 0.02% | 0.00% | Jun 2026 |
| Deutsche Bank AG | 800.00 | 0.01% | 0.00% | Jun 2026 |
| Versant Capital Management Inc | 761.00 | 0.01% | 0.00% | Jun 2026 |
Scilex Holding Company company profile
- Company name
- Scilex Holding Company
- Ticker
- SCLX.US
- Exchange
- USA Stocks
- Listed since
- Mar 5, 2021
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 34
- Fiscal year end
- December
- Address
- 960 San Antonio Road, Palo Alto, CA, United States, 94303
- Phone
- 650 516 4310
- Website
- scilexholding.com
About Scilex Holding Company
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia. It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA; and Tulex Master, which develops, tests, and manufactures clinical supplies of SP-104. Scilex Holding Company is based in Palo Alto, California.
Scilex Holding Company management
6- Dr. Henry H. Ji Ph.D.CEO, President & Executive Chairman · born 1964
- Mr. Stephen MaSenior VP, CFO, COO, Corporate Secretary & Director · born 1973
- Dr. Suketu D. Desai Ph.D.Interim Chief Technical Officer & Senior VP · born 1965
- Ms. Gigi DeGuzmanVP & Chief People Officer
- Mr. Suresh K. KhemaniSenior VP, Chief Commercial Officer & GM of Scilex Pharma · born 1960
- Dr. Dmitri V. Lissin M.D.Senior VP of Clinical Development and Medical Affairs & Interim Chief Medical Officer · born 1959